Key points are not available for this paper at this time.
PCSK9 is an established target for cholesterol-lowering therapies. Further study of PCSK9 regulatory mechanisms may identify additional control points for pharmacological inhibition of PCSK9-mediated LDLR degradation. PCSK9 function could reflect ancient roles in the fasting-feeding cycle and in linking lipoprotein metabolism with innate immunity.
Building similarity graph...
Analyzing shared references across papers
Loading...
Thomas A. Lagace (Fri,) studied this question.
synapsesocial.com/papers/69e3d452e52bf159f3b7393a — DOI: https://doi.org/10.1097/mol.0000000000000114
Thomas A. Lagace
University of Ottawa
Current Opinion in Lipidology
University of Ottawa
Building similarity graph...
Analyzing shared references across papers
Loading...